Hormonal
GLP-1 agonists (Semaglutide, Liraglutide) and dual GIP/GLP-1 agonists (Tirzepatide) are potential pharmacotherapies for MASLD/MASH due to their metabolic effects and ability to induce weight loss.
GLP-1 and GIP/GLP-1 agonists (like Semaglutide and Tirzepatide) are promising treatments for MASLD because they drive significant weight loss and improve metabolic health. They are often used in patients with Type 2 Diabetes. Oral options exist for Semaglutide.
Drugs from the group of glucagon-like peptide (GLP)-1 agonists that are normally used in the treatment of type 2 diabetes mellitus, such as semaglutide, liraglutide, and tirzepatide, are also potentially useful drugs in the treatment of MASLD/MASH due to their numerous metabolic effects... Semaglutide leads to significant weight loss in patients taking it, which also enables the aforementioned role.
Why this rating
Described as 'potentially useful' and 'studied', but specific histological outcome data for liver resolution is less detailed in this text compared to OCA.
Source
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Marija Branković et al. · Diagnostics · 2024
DOI 10.3390/diagnostics14020229
More from this paper
- Obeticholic acid (25 mg/day) improves liver fibrosis in patients with MASH and stage 2-3 fibrosis, but does not significantly resolve MASH activity compared to placebo.Good
- Pioglitazone (PPAR-gamma agonist) resolves MASH and reduces fibrosis stage, but its use is limited by adverse effects including fluid retention, weight gain, and osteopenia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →